protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility.
Through controlled ovarian stimulation
, a larger number of oocytes are made available for fertilisation.
Since the possible standardization for GnRH agonist trigger criteria that will yield optimal outcomes have not yet been established, some authors used increased estradiol levels as a criterion (20), whereas others assessed only excess number of available follicles during the late follicular phase of ovarian stimulation
Knowledge about the extent of risk associated with ovarian stimulation
, specifically in relation to gynecological malignancies is important for women considering IVF treatment and needs to be addressed by multicenteric double blind randomized placebo controlled trial on large number of subjects.
Thereafter, ovarian stimulation
was commenced for the study population as follows: group A: 40 patients who received hMG (Menogon[R], Ferring Pharmaceuticals A/S, Copenhagen, Denmark); group B: 40 patients who received hFSH (Fostimon[R], IBSA Institut Biochimique SA, Geneva, Switzerland); group C: 40 patients who received rFSH (Gonal-F[R], Merck, Serono, Rome, Italy); and group D: 40 patients who received hFSH (FostimonX[R], IBSA Institut Biochimique SA, Geneva, Switzerland) for the first 6 days, followed by rFSH (Gonal-F[R], Merck, Serono, Rome, Italy).
The significance of coasting duration during ovarian stimulation
for conception in assisted fertilization cycles.
Supraphysiological ovarian stimulation
results in E[sub]2 levels greater than those in natural conception (NC) cycles and causes E[sub]2 levels in the early stage to be similar to those in the late stage of the first trimester of NC.
The following year, 2013, was marked with the use of Kisspeptin (low risk IVF treatment) with the purpose of ovarian stimulation
which reduced the risk from hyper-stimulation syndrome.
Although ovarian stimulation
with letrozole was safe overall, the number of live births was reduced when treatment with letrozole was compared with clomiphene or Gn, and the multiple pregnancy rate for letrozole fell between the rates for clomiphene and Gn.
AMH is becoming the biomarker of choice for predicting response to controlled ovarian stimulation
The effect of dosages of gonadotrophin on ovarian stimulation
and embryo production parameters was examined by one-way analysis of variance using SPSS software (version 16.
To facilitate the process women are given a course of Follicle-Stimulating Hormone injections (FSH), which help to stimulate ovarian production, this is known ovarian stimulation